HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 793-804 of 1,811
Drug study icon
CompletedNCT00429273

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

Official study title

An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years

This study has finished and is no longer accepting participants.

In Los Angeles
ADHDMedication studyAges 7–14
Countries
United States
Sponsor
University of California, Los Angeles
Drug study icon
CompletedNCT00556959

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Official study title

A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

This study has finished and is no longer accepting participants.

Multiple locations, including Gainesville
ADHDMedication studyAges 6–17
Countries
United States
Sponsor
Addrenex Pharmaceuticals, Inc.
Other study type icon
CompletedNCT01855984

Tocotrienols for School-going Children With ADHD

Official study title

Tocotrienols Supplementation in School Going Children With Attention Deficit/Hyperactivity Disorder(ADHD) - A Randomized Controlled Trial

This study has finished and is no longer accepting participants.

In George Town
ADHDPlacebo comparisonAges 6–12
Countries
Malaysia
Sponsor
RCSI & UCD Malaysia Campus

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.